The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy

• Published in: Cancer medicine (Malden, MA) Vol. 9; no. 1; pp. 43 - 51
• Main Authors: Park, Hyunkyung, Bang, Ju‐Hee, Nam, Ah‐Rong, Park, Ji Eun, Jin, Mei Hua, Bang, Yung‐Jue, Oh, Do‐Youn
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.01.2020; John Wiley and Sons Inc; Wiley
• Subjects: Antigens; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; biomarker; Biomarkers; Biomarkers, Tumor - blood; Blood; Blood platelets; Chemotherapy; Clinical Cancer Research; Diagnosis; Disease Progression; Female; Fluorouracil - therapeutic use; Growth factors; Humans; Irinotecan - therapeutic use; Kaplan-Meier Estimate; Laboratories; Leucovorin - therapeutic use; Lymphocytes; Male; Medical prognosis; Metastasis; Middle Aged; Neutrophils; Original Research; Oxaliplatin - therapeutic use; Palliative Care - methods; Pancreatic cancer; Pancreatic Neoplasms - blood; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - mortality; Pathogenesis; Patients; Prognosis; Progression-Free Survival; Prospective Studies; Survival; Transforming Growth Factor beta - blood; Transforming growth factor-b; transforming growth factor‐beta; transforming growth factor-beta; pancreatic cancer; biomarker; chemotherapy; prognosis
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.2677

Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enrolled 60 patients treated with FOLFIRINOX as the first‐line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF‐β using an enzyme‐linked immunosorbent assay. Results The patients’ median overall survival (OS) and progression‐free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5‐12.1) and 6.5 (95% CI, 4.9‐8.1) months, respectively. Patients with low sTGF‐β at diagnosis (<31.2 ng/mL) had better OS and PFS than patients with high sTGF‐β, respectively, (OS, 13.7 vs 9.2 months; hazard ratio [HR], 2.602; P = .004; PFS, 9.0 vs 5.8 months; HR, 2.010; P = .034). At the time of disease progression, sTGF‐β was increased compared with that of diagnosis (mean, 26.4 vs 23.9 ng/mL). In particular, sTGF‐β was significantly increased at disease progression in patients with a partial response (mean, 25.7 vs 31.0 ng/mL; P = .049). Conclusions Pretreatment sTGF‐β levels can serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Likewise, the dynamics of sTGF‐β during chemotherapy have prognostic value. Pre‐treatment sTGF‐β levels serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. The dynamics of sTGF‐β during chemotherapy have prognostic value.